drugset / Trial / NCT06644183
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Phase 1/2
Recruiting
64 enrolled
Jennifer R. Brown, MD, PhD
United States Department of Defense · collab
RandomizedSequentialOpen-labelTreatment
Summary
This research study will test the safety and anticancer activity of the combination of three drugs (Roginolisib, Venetoclax, and Rituximab) for participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL). The names of the study drugs involved in this study are: * Roginolisib (a novel type of PI3-kinase delta inhibitor) * Venetoclax (a type of B-cell lymphoma 2 inhibitor) * Rituximab (a type of monoclonal antibody)
Timeline
- Start
- 2025-03-19
- Primary completion
- 2028-10-01
- Completion
- 2032-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | roginolisib | Small molecule | 40 mg | Oral |
| Background | Rituximab | Monoclonal antibody | — | Intravenous |
| Background | Venetoclax | Small molecule | — | Oral |